We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Optofluidic Device Quantifies CTCs in Blood

By LabMedica International staff writers
Posted on 25 Jul 2017
Researchers have developed a portable device that rapidly detects and counts circulating tumor cells (CTCs) in blood samples. It can help provide early diagnosis and help assess a patient’s level of health with convenient, inexpensive, effective testing for monitoring patients with cancer.

These patients need to be constantly monitored during treatment to assess disease progression, particularly if their cancer has metastasized. Monitoring is currently done using imaging techniques and biopsies, which are invasive and not always possible. In contrast, the new device is highly sensitive and requires no surgery or treatment involving radiation, thus improving patient quality of life.

Image: The device employs two systems in miniature: a flow system and an optical system. The ratio of the two systems provides a quantitative indication about how the cancer is progressing (Photo courtesy of the Universitat Rovira i Virgili).
Image: The device employs two systems in miniature: a flow system and an optical system. The ratio of the two systems provides a quantitative indication about how the cancer is progressing (Photo courtesy of the Universitat Rovira i Virgili).

The device was developed by a team of researchers and clinicians led by Universitat Rovira i Virgili (Tarragona, Catalonia, Spain) professors Francesc Díaz, Ramon Álvarez Puebla, and Jaume Masons and by HM Torrelodones University Hospital’s Dr. Eduardo García–Rico. It counts the number of tumor cells in a blood sample in real time, and has been successfully tested on patients in various stages of breast cancer. It can be adapted for use to determine the presence of other tumors by analyzing for different antibodies in the blood sample.

The patented device has been licensed for commercialization to Medcom Science, a company engaged in research and development of technologies for diagnosing and treating cancer.

The study, by Pedrol E et al, was published June 16, 2017, in the journal Scientific Reports.

Related Links:
Universitat Rovira i Virgili


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9

Latest Pathology News

Researchers Evaluate Automated Tissue Analysis Across Four Cancer Types
25 Jul 2017  |   Pathology

AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
25 Jul 2017  |   Pathology

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
25 Jul 2017  |   Pathology